Vertex Pharmaceuticals Q3 Revenue Grows 12% to $3.44 Billion

Key Facts

Vertex Pharmaceuticals' Q3 revenue rose 12% year-over-year to $3.44 billion. FX Empire reported that the growth was primarily fueled by strong performance in the company's cystic fibrosis franchise and the introduction of new products including CASGEVY, PALSONIFY, and JOURNAVX. Consequently, the company raised its full-year revenue guidance to a top end of $13.25 billion.

VRTX closed at $530.76 on November 3, 2026, having reached a session high of $561.96. These financial results follow the company reporting non-GAAP earnings per share of $4.76, representing a 0.8% year-over-year decline, while adjusted operating income grew by 2% to reach $1.41 billion.